BACKGROUND: cAMP plays a critical role in regulating cardiomyocyte survival. Various cAMP signaling pathways behave distinctly or in opposition. We have previously reported that activation of cAMP hydrolysis by cyclic nucleotide phosphodiesterase 1C (PDE1C) promotes cardiomyocytes death/apoptosis, yet the underlying molecular mechanism remains unknown. In this study, we aimed to identify the specific cAMP signaling pathway modulated by PDE1C and determine the mechanism by which Ca 2+ /calmodulin-stimulated PDE1C is activated.
C
ardiomyocyte death is associated with many cardiac diseases, including myocardial infarction, ischemia-reperfusion injury, chemotherapy-induced cardiotoxicity, myocarditis, and heart failure. 1, 2 Loss of cardiomyocytes causes contractile dysfunction, arrhythmia, inflammation, fibrosis, and ultimately heart failure. [3] [4] [5] Thus, new therapeutic strategies that target cell death and promote survival are in high demand. The second messenger cAMP plays a critical role in regulating cardiomyocyte survival and death. cAMP can be produced through the stimulation of various G-protein-coupled receptors that couple to different membrane-associated adenylyl cyclases (ACs), or through direct stimulation of soluble AC by bicarbonate. cAMP degradation can be catalyzed by diverse cyclic nucleotide phosphodiesterases (PDEs). Different sources of cAMP can have distinct or opposing functions in cardiomyocytes. For example, β-adrenergic receptor 1-derived cAMP promotes myocyte death, 6, 7 whereas adenosine A 2 receptor (A 2 R)-derived cAMP does the opposite. 8, 9 Cyclic nucleotide phosphodiesterases (PDEs) function as critical modulators in regulating the amplitude, duration, and compartmentalization of cyclic nucleotide signaling. PDEs constitute a superfamily of enzymes with 21 different genes and >100 variants grouped into 11 broad families (PDE1-PDE11) based on distinct structural, kinetic, regulatory, and inhibitory properties. Different PDEs play varied roles in cardiac remodeling and dysfunction. 10, 11 PDE1 represents the highest PDE activity in human myocardium. 12, 13 PDE1 family members are encoded by 3genes, PDE1A, PDE1B, and PDE1C, with PDE1A and PDE1C expressed in the heart. 13, 14 We have previously reported that PDE1C expression is increased in failing mouse and human hearts. 15 Using PDE1C-deficient mice, we previously demonstrated that PDE1C plays a causative role in pathological cardiac remodeling, involving myocyte hypertrophy, myocyte death, fibrosis, and cardiac dysfunction induced by chronic pressure overload, 15 yet the underlying molecular mechanisms remain uncharacterized. Here we have attempted to unveil the mechanism by which PDE1C regulates cardiomyocyte death/apoptosis. Through a variety of in vitro and in vivo approaches, we demonstrated that the activation of PDE1C by receptor potential-canonical (TRPC) channel-derived Ca 2+ negatively regulates cardioprotective A 2 R-derived cAMP signaling. Furthermore, we characterized a multiprotein complex containing PDE1C, A 2A R, and TRPC3 localized proximal to the cell membrane and possibly T tubules. Coordination of these proteins into a complex allows precise control of cAMP signaling for myocyte survival. It is important to note that these mechanistic studies may provide novel insights into using combination therapy to promote synergistic effects on myocyte survival.
METHODS
All animal procedures were performed in accordance with the National Institutes of Health and University of Rochester institutional guidelines. An expanded Methods section is available in the online-only Data Supplement. The data, methods, and materials will be available to others for purposes of reproducing the results or replicating procedures by contacting the corresponding author.
Animal Models
Global PDE1C knockout (PDE1C-KO) mice were backcrossed to C57BL/6J mice for >10 generations. For experiments with genetically modified mice, age/sex/genetic backgroundmatched mice were randomly separated into indicated groups based on animal identification number. For the Ang II infusion model, PDE1C-KO and wild-type (PDE1C-WT) mice from sibling mating at 10 to 12 weeks of age were subjected to subcutaneous infusion with vehicle saline or Ang II (1.4 mg/kg/day) for 28 days as described previously. 16 For the doxorubicin cardiac
Clinical Perspective
What Is New?
• Phosphodiesterase 1C (PDE1C) functions as a key negative regulator of the adenosine-cAMP signaling in cardiomyocytes, a well-characterized cardioprotective signaling pathway.
• Transient receptor potential-canonical channel member 3 (TRPC3), PDE1C, and adenosine A2A receptor (A 2A R) are coordinated in a novel macromolecule complex localized to cardiomyocyte membranes and perhaps T tubules, offering a novel mechanism by which Ca 2+ influx negatively regulates G-protein-coupled receptors-cAMP signaling via activation of Ca 2+ -dependent PDE1C.
• Low doses of A 2 R agonist combined with PDE1 or TRPC inhibitor provide synergistic effects on myocyte survival.
• PDE1 inhibition or PDE1C deficiency protects against doxorubicin-induced cardiac toxicity and dysfunction in vivo, which is dependent on A 2 R activation.
What Are the Clinical Implications?
• Our findings suggest that PDE1C may represent a novel therapeutic target for various cardiac diseases associated with cardiomyocyte death. • PDE1C inhibition may represent a novel therapeutic strategy in cancer therapy, by which PDE1C inhibition blocks cancer cell growth while simultaneously preventing cardiac toxicity.
• It may be possible to achieve synergistic protective effects against cardiomyocyte death by simultaneously activating the positive cAMP regulator A 2 R and inhibiting the negative cAMP regulator PDE1C or TRPC. ORIGINAL RESEARCH ARTICLE toxicity model, PDE1C-WT, PDE1C-KO, or C57BL/6J male or female mice 10 to 12 weeks of age were randomly separated into indicated groups. Doxorubicin (20 mg/kg in saline) was administered via intraperitoneal injection (IP) in a single bolus. IC86340 (6 mg/kg/day) and ZM241385 (10 mg/kg/day) in 20% DMSO/buffered saline were injected via IP 2 days before doxorubicin treatment and continued for an additional 5 days. Mouse cardiac function was measured by echocardiography before sacrifice. Echocardiography was monitored in anesthetized mice using a Vevo2100 echocardiography machine equipped with an MS-550D 40 MHz frequency probe (VisualSonics) as described previously in a blinded manner.
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Adult Mouse Cardiomyocyte Isolation and Culture
Adult mouse cardiomyocytes were isolated by enzymatic dissociation using collagenase type II (Worthington) in a Langendorff perfusion system as previously described. 15 Cardiomyocytes were cultured in the presence of blebbistatin (a myosin II inhibitor) to block myocyte contraction and extend their survival during the culture as described previously. 15 Cardiomyocyte death/apoptosis was induced by indicated reagents for 24 to 48 hours. Cell death/apoptosis was measured by trypan blue staining, TUNEL staining, or caspase-3/7 activity assay.
Trypan Blue Viability Assay
Trypan blue staining was performed as described previously. 15 At the end of treatments, cells were centrifuged at 1000g for 3 minutes, stained with Trypan blue solution (0.2%) for 5 minutes, and photographed. Twenty fields were randomly selected, and an average of 300 myocytes was counted for each dish.
Coimmunoprecipitation
Coimmunoprecipitation experiments were performed with the immunoprecipitation kit (ThermoFisher) based on the manufacturer's protocol. To reduce interference of IgG light or heavy chain, mouse TrueBlot ULTRA: Anti-Mouse IgG HRP and sheep TrueBlot: Anti-sheep IgG HRP (Rockland) were used as secondary antibodies for immunoblotting.
Statistics
All data are presented as mean±SEM. Statistical analysis was performed using SPSS 20.0. The unpaired Student's t test was used for comparisons between 2 groups, whereas 1-way ANOVA followed by Bonferroni's post hoc test were used for comparisons among multiple groups. P values <0.05 were considered significant.
RESULTS
PDE1C But Not PDE1A Regulates Adult Mouse Cardiomyocyte Survival
We have previously found that PDE1C deficiency or treatment with the pan PDE1 inhibitor IC86340 attenuated Ang II and isoproterenol (ISO)-stimulated adult mouse cardiomyocyte death and apoptosis in vitro. 15 Because 2 PDE1 family members, PDE1A and PDE1C, are expressed in cardiomyocytes, 14 we examined their differential roles in cardiomyocyte death. Using the trypan blue staining method, we showed that Ang II-induced cell death was significantly induced in WT mouse adult cardiomyocytes, which was abolished in PDE1C-KO but not PDE1A-KO myocytes ( Figure I in the online-only Data Supplement). Similar to Ang II, doxorubicin and H 2 O 2 -stimulated cell death were also blocked in PDE1C-KO but not in PDE1A-KO myocytes ( Figure I in the online-only Data Supplement). Together these results suggest that PDE1C exclusively regulates cardiomyocyte death in response to multiple stimuli.
PDE1C Deficiency Reduces Apoptotic Cardiomyocytes in Mouse Hearts With Chronic Ang II Infusion
To determine the effects of PDE1C deficiency on Ang II-induced cardiomyocyte death in vivo, we subjected PDE1C-WT or PDE1C-KO mice to chronic vehicle or Ang II infusion and assessed cardiomyocyte apoptosis via TUNEL staining. PDE1C deficiency did not have an effect on blood pressure (data not shown), which is consistent with the finding that PDE1C is not expressed in contractile smooth muscle cells in normal vessel walls. 17 We found that cardiomyocyte apoptosis was significantly increased in Ang II-treated PDE1C-WT hearts compared with vehicle, which was significantly attenuated in PDE1C-KO hearts ( Figure II in the onlineonly Data Supplement). This result is consistent with our previous finding in thoracic aorta contraction-induced heart failure, 15 suggesting that PDE1C deficiency is protective against myocardial death in multiple forms of cardiac disease models.
The Protective Effects of PDE1C Inhibition or Deficiency on Cardiomyocyte Death and Apoptosis Are Dependent on A 2 R Activation
To further investigate the anti-apoptotic mechanism of PDE1C inhibition, we first examined whether PDE1C regulates adenosine-cAMP signaling, which was previously found to mediate myocyte survival. 8 We confirmed that adenosine dose-dependently inhibited Ang II-induced myocyte death ( Figure III in the online-only Data Supplement). There are 4 adenosine receptors: A 1 R, A 2A R, A 2B R, and A 3 R. 8 Among them, A 2A R and A 2B R are coupled to Gα s , which stimulates cAMP production and therefore represent promising targets for PDE1C. To determine whether A 2 R-cAMP signaling is involved in PDE1C-mediated regulation of myocyte survival, we first use a high dose of ZM241385 (200 nmol/L), which is able to block both A 2A R and A 2B R subtypes at high doses. When we measured myocyte death by trypan blue staining ( Figure 1A ), the protective effect of the PDE1 inhibitor IC86340 on Ang II-induced cell death seen in PDE1C-WT myocytes was almost completely abolished when blocking A 2 R with ZM241385 ( Figure 1B ). Consistently, the protective effect of PDE1C deficiency was also reversed on A 2 R blockade ( Figure 1C ). These results suggest that the protective effects of PDE1C deficiency/ inhibition on myocyte death are dependent on A 2 R activation.
Because trypan blue only allows for nonspecific assessment of cell death and viability, we next examined myocyte apoptosis by TUNEL staining and caspase 3/7 activities. As shown in Figure 2A through 2C, the antiapoptotic effects of IC86340 or PDE1C deficiency were completely abolished by treatment with A 2 R antagonist ZM241385. In addition, the reduced caspase 3/7 activity seen with PDE1 inhibition ( Figure 2D ) or PDE1C deficiency ( Figure 2E ) was also completely abolished under A 2 R blockade. These findings also confirmed that Trypan blue staining is a valid method for assessing cell death in adult cardiomyocytes in vitro. Therefore, we used it for the majority of further experiments investigating cell death.
We next determined the specific contributions of A 2A R or A 2B R to PDE1C-regulated protective signaling. 
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subtypes may act as hetero-oligomers or in other forms of cooperativity.
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Stimulating cardiomyocytes with PGE 2 can increase cAMP. Gα s -coupled EP4 represents the most dominant subtype expressed in the heart, 19 and the cardiac protective effects of EP4 on ischemia-reperfusion injury and cardiac remodeling have been documented. [20] [21] [22] It is interesting to note that we found that treatment with an EP4 antagonist failed to block the protective effect of PDE1C deficiency on myocyte death ( Figure IVD in the online-only Data Supplement). The effectiveness of this EP4 antagonist was confirmed in a separate myocyte hypertrophy study (data not shown). This finding supports the notion of selective interaction between PDE1C and a cAMP pool coupled to A 2 R.
Given the functional interaction between PDE1C and adenosine-cAMP signaling, we examined whether activation of A 2 R and inhibition of PDE1C have syner- Figure 4B ), yet in combination, they synergistically inhibited cell death and apoptosis. This synergistic protective effect was blocked by treatment with the A 2A R blocker ZM241385 (5 nmol/L) or A 2B R blocker PSB603 (100 nmol/L) ( Figure 4C ). Besides adenosine, low doses of the A 2 R-selective agonist CGS21680 with IC86340 also elicited a synergistic effect, which again was abolished by A 2 R blockade ( Figure 4D ), further supporting the notion of an A 2 receptor-PDE1C-specific module.
TRPC Is Involved in PDE1C-Mediated Regulation of Cardiomyocyte Death
We next investigated how PDE1C is activated by Ang II. PDE1C is a Ca 2+ /calmodulin-stimulated PDE. It has been shown that the canonical transient receptor potential TRPC3 is responsible for both stress-induced and Ang II type 1 receptor (AT1R)-dependent slow increases of intracellular Ca 2+ in mouse cardiomyocytes.
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TRPC3 also plays a critical role in cardiomyocyte apoptosis in response to ischemia-reperfusion. 24 Therefore, we interrogated the role of TRPC3 channels in Ang II-induced cell death with the nonselective TRPC channel blocker SFK96365, as well as the TRPC3-selective blocker Pyr3. We found that both SFK96365 and Pyr3 inhibited Ang II-induced cell death similarly in WT myocytes ( Figure 5A ), but it had no further effects on PDE1C-KO myocytes ( Figure 5B ). We then tested the effect of suppressing TRPC3 expression via lentivirus shRNA vectors, which reduced TRPC3 expression by ≈70% relative to control scramble shRNA (Figure VA in the online-only Data Supplement). TRPC3 shRNA had similar effects as the TRPC3 inhibitor Pyr3 on cell death in WT and PDE1C-KO myocytes ( Figure 5C and 5D). These results suggest that TRPC3 and PDE1C regulate cell death in a redundant manner or via the same signaling pathway.
To further confirm the role of TRPC3, we overexpressed TRPC3 in WT myocytes ( Figure VB in the online-only Data Supplement) and found that cells were sensitized to Ang II-stimulated cell death ( Figure 5E ). The TRPC3 inhibitor Pyr3, PDE1 inhibitor IC86340, and extracellular Ca 2+ chelator EGTA each completely abolished Ang II-stimulated cell death under TRPC3 overexpression ( Figure 5E ).To further determine the role of TRPC3 in PDE1C-mediated regulation of myocyte death, we ectopically expressed PDE1C via an adeno- 
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viral vector in PDE1C-KO myocytes to a level roughly equivalent to that in WT myocytes, as evaluated by Western blotting and immunostaining ( Figure VC and VD in the online-only Data Supplement). We found that PDE1C expression resensitized myocytes to Ang II-stimulated cell death, which was abolished by Pyr3, IC86340, or EGTA ( Figure 5F ). These results strongly suggest that PDE1C's function on myocyte death is dependent on TRPC3 activation and extracellular Ca 2+ , which also provides an explanation for our findings that inhibition of PDE1C and TRPC3 act redundantly, with no additive effect on myocyte death. In support of this notion, we also found that neither adenosine nor SKF96365 treatment at low doses alone had any visible effect on cell death, but in combination they synergisti- 
TRPC and PDE1C Are Involved in Ang II-Mediated Reduction of cAMP in Cardiomyocytes
Subsequently, we investigated the role of PDE1C in regulating myocyte cAMP. We found that in WT myocytes, Ang II treatment rapidly induced a reduction in cAMP, which was abolished by PDE1 inhibition with IC86340 or TRPC3 inhibition with Pyr3 ( Figure 5G) , and IC86340 together with Pyr3 did not have additive effects on cAMP levels ( Figure 5G ). However, Ang II failed to reduce cAMP in PDE1C-KO myocytes ( Figure 5H ), , 100 nmol/L), TRPC3 inhibitor (Pyr3, 100 nmol/L), or vehicle for 24 hours. C and D, cardiomyocytes from PDE1C-WT or PDE1C-KO mice were treated with lentivirusexpressing TRPC3 shRNA or scramble shRNA for 48 hours and followed by Ang II treatment for an additional 24 hours. Cell death was detected by trypan blue staining. E and F, PDE1C-WT cardiomyocytes were treated with lentivirus-expressing GFP or TRPC3 for 48 hours or PDE1C-KO cardiomyocytes were treated with adenovirus-expressing LacZ or PDE1C1 for 48 hours. Cells were then treated with Ang II (200 nmol/L), Pyr3 (100 nmol/L), IC86340 (15 µmol/L), or EGTA (1 µmol/L) as indicated for 24 hours. Cell death was detected by trypan blue staining. G and H, Cardiomyocytes isolated from PDE1C-WT or PDE1C-KO mice were pretreated with IC86340, Pyr3, or vehicle for 30 minutes, followed by Ang II stimulation for 15 minutes. Cells were then lysed and cAMP levels were measured via AlphaScreen assay. Data are presented as mean±SEM. *P<0.05 by 1-way ANOVA with Bonferroni's correction. A and C, n=6 replicates from 3 mice. B, D, E, and F, n=5 replicates from 3 mice. G and H, n=3 replicates from 3 mice. Ang indicates angiotensin II; cAMP, cyclic adenosine monophosphate; GFP, green fluorescent protein; KO, knockout; PDE, phosphodiesterase; TRPC, transient receptor potential-canonical; and WT, wild type.
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treatment induces cardiomyocyte Ca 2+ entry, activating PDE1C and resulting in a loss of cAMP that is coupled to A 2 R activation.
PDE1C, A 2 R, and TRPC3 Form a Multiprotein Complex in Cardiomyocyte Membrane
TRPC3 is primarily localized to T tubules. 25 Because of the functional relationship between TRPC3 and PDE1C, we investigated the localization of PDE1C. We found that endogenous PDE1C staining largely overlapped with the Na + /Ca 2+ exchanger, which also primarily localizes to T tubules ( Figure VII in the online-only Data Supplement), suggesting that PDE1C may as well. Having observed functional coupling among PDE1C, A 2 R, and TRPC3, we hypothesized that PDE1C is localized in proximity with A 2 R and TRPC3. We therefore performed coimmunostaining for endogenous PDE1C, A 2A R, and TRPC3 in cardiomyocytes and heart tissues. Triple immunostaining and 3-color histogram analysis revealed significant colocalization among PDE1C, A 2A R, and TRPC3 in isolated cardiomyocytes ( Figure 6A and 6B). PDE1C/A 2A R or PDE1C/TRPC3 double staining also revealed significant overlap between PDE1C and A 2A R ( Figure 6C and 6D) , as well as PDE1C and TRPC3 in heart tissues ( Figure 6E and 6F). These findings suggest that PDE1C is present in proximity with A 2A R and TRPC3 in cardiomyocytes. Because of the difficulty in finding a specific A 2B R antibody for immunostaining, we focused on A 2A R.
Next, we performed coimmunoprecipitation assays to further demonstrate the association among PDE1C, A 2A R, and TRPC3. When immunoprecipitating PDE1C in WT or PDE1C-KO heart samples with PDE1C antibody, we were able to detect A 2A R and TRPC3 by Western blotting in WT but not PDE1C-KO heart lysates (Figure 6G) . Consistently, when pulling down TRPC3 in WT heart samples with TRPC3 antibody or IgG, we were able to detect PDE1C and A 2A R with TRPC3 antibody but not IgG ( Figure 6H ). Furthermore, when pulling down A 2A R in WT or A 2A R-KO heart samples, we were able to detect PDE1C and TRPC3 in WT but not A 2A R-KO heart samples ( Figure 6I ). These results suggest that PDE1C, A 2A R, and TRPC3 are present in the same multiprotein complex.
We next investigated the specific interactions between these proteins. We pulled down TRPC3 in WT and PDE1C-KO heart lysates and detected A 2A R in both samples ( Figure VIIIA in the online-only Data Supplement), suggesting that the association between TRPC3 and A 2A R is independent of PDE1C. Similarly, we pulled down TRPC3 in WT and A 2A R-KO heart lysates and detected PDE1C in both WT and A 2A R-KO samples ( Figure  VIIIA in the online-only Data Supplement), suggesting that the association between TRPC3 and PDE1C is independent of A 2A R. These results may suggest that these 3 proteins do not directly interact with each other, and that other scaffold protein(s) are important for the complex formation.
A 2 R Activation Is Critical for the Protective Effects of PDE1C Inhibition or PDE1C Deficiency on Doxorubicin-Induced Cardiomyocyte Death in Vitro as Well as Cardiac Toxicity and Dysfunction in Vivo
The anthracycline doxorubicin (DOX) is a well-known chemotherapy drug that causes cardiotoxicity, ultimately leading to heart failure. 26 DOX induces cardiomyocyte death, 1 of the mechanisms responsible for DOXinduced cardiac atrophy and functional impairment. 27 Given our findings that PDE1C and A 2 R regulate cardiomyocyte death, we investigated whether they could also modulate DOX-induced cardiotoxicity. Similar to Ang II-induced myocyte death, the PDE1 inhibitor IC86340 ( Figure 7A ) or PDE1C deficiency ( Figure 7B ) significantly inhibited DOX-induced myocyte death in vitro. This protective effect was also abolished by A 2 R antagonism with ZM241385.
We next investigated the protective effects of IC86340 and the role of A 2 R on DOX-induced cardiomyopathy and cardiac dysfunction in vivo. Consistent with previous studies, cardiac atrophy was induced by a single dose of DOX, as evidenced by significant reductions in heart size ( Figure 7C ) and weight ( Figure 7D) . Treatment with the PDE1 inhibitor IC86340 prevented this atrophy, yet this protective effect was reversed by treatment with A 2 R antagonist ZM241385. Histological analyses revealed that myocyte apoptosis, assessed by TUNEL staining, was markedly increased by DOX treatment ( Figure 7E and 7F) . IC86340 protected from DOXinduced myocyte apoptosis, yet it failed to do so in the presence of ZM241385. Echocardiographic measurements showed that DOX caused a significant loss in cardiac contractile function, reflected by reduced fractional shortening and ejection fraction and an increase in left ventricular end systolic diameter, each of which was significantly improved by IC86340 but not by IC86340 with ZM241385 ( Figure 7G and Figure IXA through IXD in the online-only Data Supplement). Cardiac troponin I, a circulating marker of cardiac damage, was altered in a similar pattern ( Figure 7H ). Moreover, IC86340 increased the survival rate of mice compared with the DOX treatment group, yet this increase was lost in the group treated with DOX, IC86340, and ZM241385 ( Figure IXE in the online-only Data Supplement).
We also investigated the protective effects of PDE1C deficiency and the role of A 2 R in the DOX model in vivo. Similar to PDE1 inhibition, PDE1C deficiency also protected against cardiac atrophy as assessed by heart size/ weight change ( Figure 8A and 8B) , myocyte apoptosis ( Figure 8C and 8D) , cardiac contractile dysfunction including reduced fractional shortening ( Figure 8E 
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PDE1C deficiency ameliorates cardiac structural and functional deterioration and improves survival of mice after treatment with DOX, which is dependent on A 2 R activation.
DISCUSSION
In this study, we have investigated the mechanism by which PDE1C protects against cardiomyocyte death/ 
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apoptosis in vitro and in vivo, primarily focusing on defining proximal positive and negative regulators of the cardioprotective cAMP-signaling module. The present study has revealed a number of novel findings, summarized as follows: (1) PDE1C activation promotes cardiomyocyte death/apoptosis by antagonizing a novel myocyte protective cAMP signaling pathway that is derived from activation of the adenosine receptors A 2A R/A 2B R; (2) PDE1 inhibition or PDE1C deficiency elicits protective effects on DOX-induced cardiomyopathy and dysfunction in vivo, consistent with its central role in regulating cardiomyocyte death, and these protective effects are dependent on A 2 R, consistent with the findings in isolated cardiomyocytes; (3) PDE1C, as a Ca 2+ /CaM-stimulated PDE, is likely activated by TRPC3-mediated extracellular Ca 2+ influx, and PDE1C, A 2A R, and TRPC3 are physically and functionally associated and form a macromolecule complex that is localized proximate to the cell membrane and T tubules. Our discovery of this complex has offered a novel mechanism by which Ca 2+ influx regulates G-protein-coupled receptors-cAMP signaling via Ca 2+ -stimulated PDE1C activation; and (4) simultaneously activating A 2 R and inhibiting PDE1C or TRPCs can induce synergistic protective effects on myocyte death. The ability of low doses of drugs targeting these proteins to elicit potent cardioprotective effects may have therapeutic significance. Taken together, our results indicate that we have identified a cardiac protective cAMP signaling cascade that is positively regulated by A 2 R and negatively regulated by PDE1C through activation of TRPC3 ( Figure 8G ). Coordination of these proteins into a complex allows precise control of cAMP signaling for myocyte survival. Our findings may provide novel insight into using combination therapy to promote synergistic effects on myocyte survival.
Adenosine is an important regulator of the cardiovascular system. The beneficial effects of adenosine receptor (AR) stimulation in the cardiovascular system make this an attractive therapeutic target. However, the ubiquitous distribution of ARs throughout the body has posed a challenge regarding the specificity of ARbased pharmacological therapy. We found that at low doses, neither adenosine (nor A 2 R agonist) nor PDE1 inhibitor alone had any effect, yet in combination, they produced synergistic protective effects on cardiomyocytes. In addition, PDE1C displays a highly tissue-type and cell-type specific expression profile. 28, 29 Thus, our findings may support investigation of novel therapeutic strategies involving a combination treatment of lowdose A 2 R agonists and PDE1C inhibitors, which could allow specific targeting exclusively in cells or tissues where both A 2 R and PDE1C exist. Such combination treatment regimens deserve to be further evaluated in the intact heart and in vivo in the future.
TRPCs, voltage-independent cation channels, are best known for their functions related to Ca 2+ influx. In cardiomyocytes, TRPCs have been shown to play a role in coordination of signaling in local domains through interaction with Ca 2+ -dependent proteins, thus playing critical roles in pathological cardiac structure remodeling. 30, 31 The TRPC channel family is comprised of 7 members, TRPC1-TRPC7. 32 In this study, we have primarily focused on TRPC3 because it has been shown to mediate Ang II-induced Ca 2+ entry in cardiomyocytes 23 and is important for cardiomyocyte apoptosis after ischemia-reperfusion injury. 24 However, the involvement of other TRPC family members in regulating PDE1C activation cannot be excluded particularly because TRPC channels can form heterotetramers, such as TRPC1/ TRPC3, 33 TRPC1/TRPC3/TRPC7, 34 TRPC3/TRPC6, 30 and TRPC3/TRPC6/TRPC7. 35 It will be interesting to investigate the relationship between PDE1C with other TRPCs in cardiomyocytes in the future. TRPCs possess a variety of regulatory and protein integrations sites, which not only allows TRPCs to form homo-/hetero-tetramer, but also associate with and be regulated by other proteins. For example, it has been shown that PKG can phosphorylate TRPC3, which negatively regulates TRPC3 activity. 36 PKA shares the same consensus phosphorylation on the TRPC3 site as PKG. Therefore, it may be worthwhile to examine whether cAMP/PKA is able to negatively regulate TRPC3 through feedback signaling.
The PDE1 inhibitor IC86340 is able to inhibit all PDE1 family members. In cardiomyocytes, both PDE1A and PDE1C are expressed. Our findings from isolated cardiomyocytes indicate that PDE1C but not PDE1A regulates myocyte death, and that the protective effects of IC86340 primarily result from PDE1C inhibition ( Figure  I in the online-only Data Supplement). In support of this, we observed similar protective effects between IC86340 and PDE1C deficiency against myocyte death induced by different death stimuli, including Ang II, (Figures 7 and 8) , and transverse aortic constriction 15 in vivo. This finding suggests that PDE1C may play a critical role in diverse cardiac diseases associated with myocyte death regardless of etiology. PDE1C has also been implicated in cancer cells. For example, a focal genomic amplification at the PDE1C locus has been found in >90 human glioblastoma multiform cell lines, and PDE1C is critical for glioblastoma multiform cell proliferation, Figure 8 Continued. at the time of termination. F, Plasma troponin I (cTnI) levels. Data are presented as mean±SEM. *P<0.05 by 1-way ANOVA with Bonferroni's correction. B, D, E, and F, n= 3 to 5 for male mice and n=3 to 5 for female mice. G, Proposed model. Pathological stimuli, such as Ang II or DOX, activate TRPC3 and result in Ca 2+ influx. This serves to activate PDE1C and subsequently increases the degradation of cAMP derived from A 2 R activation, which promotes cell death. Ang indicates angiotensin II; cAMP, cyclic adenosine monophosphate; cTnI, cardiac tropnin I; IP, intraperitoneal injection; KO, knockout; PDE, phosphodiesterase; TRPC, xxx; and WT, wild type. migration, and invasion. 37 PDE1C is also important for the growth of human malignant melanoma cell lines. 38 These findings could indicate that PDE1C inhibition or suppression could reduce growth in cancer cells. Thus, the protective effects of PDE1 inhibition/deficiency on DOX-induced cardiac toxicity suggest that PDE1 inhibition may represent a novel therapeutic strategy: inhibiting cancer growth while preventing cardiotoxicity.
It is worth noting that the beneficial effects of the PDE1 inhibitor IC86340 or global PDE1C deficiency on preventing cardiotoxicity and increasing mice survival rate in DOX-treated mice may not exclusively rely on PDE1C inhibition and protection against myocyte death. In addition to cardiomyocyte apoptosis, DOX also induces cardiac atrophy, inflammation, and oxidative stress as well as toxicity in other tissues/organs, which may indirectly affect cardiac performance. Thus, the role of PDE1C or other PDE1 isozymes in other cells, tissues, and organs should also be taken into consideration. Moreover, it is still not known whether the cyclic nucleotide signaling modulated by PDE1C directly regulates cardiomyocyte contractility, which deserves to be further characterized. Adenosine exerts cardiac electrophysiological effects, which are believed to be mainly through A 1 R activation. 39 The effects of A 2 R on cardiac contractile function remain controversial. 39 Moreover, the vasodilatory function of A 2 R action 39 may also contribute to worsening myocardial damage and function by A 2 R antagonist ZM241385.
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